

Thanks to the reviewers for their valuable suggestions, our responses are as follows:

In this case report, we describe in detail the significant benefit and prolonged PFS of this patient after bevacizumab plus irinotecan.

In the discussion section, we conduct a literature review. For small-cell carcinoma chemotherapy, we reviewed two phase III clinical trials that demonstrated that the IP regimen was more effective than the EP regimen and the IC regimen was more effective than the EC regimen. For targeted drugs, we reviewed three clinical trials: ECOG3501 trial, Phase II SALUTE trial and CALGB 30306 trial, all of which demonstrated the efficacy of bevacizumab in combination with chemotherapy.

Both this case and the literature review suggest that irinotecan in combination with bevacizumab may be a promising treatment for brain metastases in SCLC.